1
Clinical Trials associated with Dual-targeting VEGFR1 and PD-L1 CAR-T cells(Sichuan University)A Phase Ia/Ib, Open-label, Single-arm, Dose-escalation and Expansion Study of Specific Dual-targeting VEGFR1 and PD-L1 CAR-T in Cancer Patients With Pleural or Peritoneal Metastases
Serosal cavity metastases of malignant tumor seriously affects the quality of life and survival time of patients with cancers in advanced stage. VEGFR1 is frequently expressed in breast cancer, ovarian cancer, lung cancer, gastric cancer and other malignant tumors and their metastases. The VEGFR1/PD-L1 dual-targeting CAR-T will be investigated in cancer patients with serosal cavity metastases.
100 Clinical Results associated with Dual-targeting VEGFR1 and PD-L1 CAR-T cells(Sichuan University)
100 Translational Medicine associated with Dual-targeting VEGFR1 and PD-L1 CAR-T cells(Sichuan University)
100 Patents (Medical) associated with Dual-targeting VEGFR1 and PD-L1 CAR-T cells(Sichuan University)
100 Deals associated with Dual-targeting VEGFR1 and PD-L1 CAR-T cells(Sichuan University)